New search data revealed a 302% increase in UK interest for ‘Mounjaro’ following the NHS's 'difficult' announcement on Thursday, 5 December 2024.
The announcement highlighted that the obese population in the UK will be facing delays in accessing Mounjaro prescriptions. The new rollout aims to provide medication to support 220,000 overweight individuals, but this accounts for less than 10% of eligible patients over the next three years.
Conducted by the weight-loss programme Second Nature, the data also showed UK public demand for ‘Mounjaro’ –the anti-obesity weight-loss drug set to be used in the rollout– has increased by over 3,450% since the beginning of the year.
Second Nature also revealed that searches for ‘weight loss jab’ and ‘weight loss drug’ have also exceeded 275% since Thursday.
Mounjaro is recommended for those with a body mass index (BMI) of more than 35 and at least one weight-related illness. The latest health survey for England reports 64% of adults in England were overweight or obese in 2022.
Commenting on the findings, Mike Gibbs, co-founder of Second Nature, said, "This upcoming weight-loss drug rollout could significantly impact the lives of many who need it. With obesity levels rising and the NHS stretched, weight-loss injections like Mounjaro are considered as potential game-changers. However, access remains limited, and managing expectations around these treatments is vital.
"Weight-loss injections are not a quick-fix solution, and they may not be effective for everyone. It's crucial to consider sustainable approaches to weight management, including balanced diets and regular exercise, alongside medical consultation. Personalised advice ensures that treatment plans are safe, effective, and suitable for your long-term health."
The announcement highlighted that the obese population in the UK will be facing delays in accessing Mounjaro prescriptions. The new rollout aims to provide medication to support 220,000 overweight individuals, but this accounts for less than 10% of eligible patients over the next three years.
Conducted by the weight-loss programme Second Nature, the data also showed UK public demand for ‘Mounjaro’ –the anti-obesity weight-loss drug set to be used in the rollout– has increased by over 3,450% since the beginning of the year.
Second Nature also revealed that searches for ‘weight loss jab’ and ‘weight loss drug’ have also exceeded 275% since Thursday.
Mounjaro is recommended for those with a body mass index (BMI) of more than 35 and at least one weight-related illness. The latest health survey for England reports 64% of adults in England were overweight or obese in 2022.
Commenting on the findings, Mike Gibbs, co-founder of Second Nature, said, "This upcoming weight-loss drug rollout could significantly impact the lives of many who need it. With obesity levels rising and the NHS stretched, weight-loss injections like Mounjaro are considered as potential game-changers. However, access remains limited, and managing expectations around these treatments is vital.
"Weight-loss injections are not a quick-fix solution, and they may not be effective for everyone. It's crucial to consider sustainable approaches to weight management, including balanced diets and regular exercise, alongside medical consultation. Personalised advice ensures that treatment plans are safe, effective, and suitable for your long-term health."
